AstraZeneca

AstraZeneca’s Fasenra Shows Major Breakthrough in Delaying HES Disease Flares

WILMINGTON, DE — AstraZeneca reported statistically significant Phase III results showing that Fasenra (benralizumab) can substantially delay disease worsening for patients with hypereosinophilic syndrome (HES), a rare and potentially life-threatening …

AstraZeneca’s Fasenra Shows Major Breakthrough in Delaying HES Disease Flares Read More


Incyte

Incyte Expands ‘Moments of Clarity’ With New Stories Spotlighting Chronic Skin Conditions

WILMINGTON, DE — Incyte (Nasdaq: INCY) has expanded its Moments of Clarity program, adding six new personal stories that illuminate the lived experiences of people managing chronic immune-mediated skin conditions, …

Incyte Expands ‘Moments of Clarity’ With New Stories Spotlighting Chronic Skin Conditions Read More